Detall de la convocatòria
Característiques
Característica |
---|
Objectiu de la convocatòria
The principal aim of this grant program is to support global research that advances the role of Sphingosine-1-phosphate (S1P) receptor modulation in the treatment of Ulcerative Colitis (UC). |
Característiques principals
Pfizer is interested in supporting research proposals that advance our understanding of ulcerative colitis through research focused in the following areas: |
Lloc de presentació
IMIM and PSMAR staff who need more information should contact: Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00. Carol Barnwell: cbarnwell@imim.es Ext.: 1670 Marta López: mlopez4@imim.es Ext.: 1576 |
Convocatòria (URL)
https://cdn.pfizer.com/pfizercom/2023-05/2023%20I&I%20Global%20UC%20Research.pdf?Mt5xMUQBiLWelNc8HI9x3_iJUs6fnpbu= |
Requisits
1. The institution and principal investigator (PI) must be based in one of the eligible countries noted above, which include select European countries, Canada, South Korea, Australia, New Zealand, and Israel. 2. Only organizations are eligible to receive grants, not individuals or medical practice groups. 3. The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. 4. Applicant must be affiliated with a host institution. 5. Both early career and experienced investigators are encouraged to apply and consideration will be given to all proposals meeting the selection criteria. |
Dotació
Individual projects requesting up to $200,000 USD will be considered. The estimated total available budget related to this RFP is $600,000 USD. |
Durada
Project length will be a maximum of 18 months. |
Arxius
Arxiu |
---|
2023 I&I Global UC Research.pdf |